Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer | Zendy

Libero Santarpia | Zendy; Adel K. ElNaggar | Zendy; Gilbert J. Cote | Zendy; Jeffrey N. Myers | Zendy; Steven I. Sherman | Zendy

Open Access

Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer

Author(s) -

Libero Santarpia,

Adel K. ElNaggar,

Gilbert J. Cote,

Jeffrey N. Myers,

Steven I. Sherman

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2007-1076

Subject(s) - pten , anaplastic thyroid cancer , cancer research , carcinogenesis , protein kinase b , mapk/erk pathway , pi3k/akt/mtor pathway , anaplastic lymphoma kinase , kinase , cancer , thyroid cancer , biology , signal transduction , medicine , genetics , lung cancer , malignant pleural effusion

Anaplastic thyroid carcinoma (ATC) can occur in the setting of differentiated thyroid carcinoma (DTC), which suggests a continuum in malignant progression from DTC to ATC. The Ras/Raf-MAPK and the phosphatidylinositol 3-kinase/Akt signaling pathways play critical roles in DTC tumorigenesis, but their roles in the pathogenesis of ATC are poorly defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research